Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 708 publications.

Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619

Doma R, Suminski N, Gold A. Landscape analysis of Alzheimer's disease-specific caregiver outcome assessments. Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S227. doi: 10.1016/j.jval.2023.09.1173

Gold A, Brouwer E, Hakkarainen KM, Brown D. A review of patient-reported outcomes and external control arms in regulatory submissions of novel oncology drugs. Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S216-7. doi: 10.1016/j.jval.2023.09.1120

Goyal RK, Candrilli SD, Abughosh SM, Chen H, Holmes HM, Johnson ML. Social Determinants of Health (SDoH) and other predictors in treatment initiation with CDK4/6 inhibitors in Medicare patients with HR+/HER2– Metastatic Breast Cancer (MBC). Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S286. doi: 10.1016/j.jval.2023.09.1502

Vickers A, Leng X. The impact of life expectancy exclusion criteria on survival curve extrapolation. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S406. doi: 10.1016/j.jval.2023.09.2131

Vickers A. The performance of anchored and unanchored population adjustment methods (matching-adjusted indirect comparison, simulated treatment comparison, and multiple imputation marginalization) in castration resistant prostate cancer. Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S400-1. doi: 10.1016/j.jval.2023.09.2098

Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S. Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S434-5. doi: 10.1016/j.jval.2023.09.2271

Ronquest N, Paret K, Mladsi DM, Lee LJ. Exploring the value of country-specific cost-effectiveness models in early stages of drug development. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S94. doi: 10.1016/j.jval.2023.09.493

Jen MH, Kiiskinen U, Khanal M, Han Y, Hess L, Tian W, Vickers A. Matching Adjusted Indirect Comparison (MAIC) of selpercatinib Vs cabozantinib in RET mutation-positive advanced Medullary Thyroid Cancer (MTC). Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S18. doi: 10.1016/j.jval.2023.09.094

Samant S, Oberle S, Marcek T, Poulos C, Chintakayala PK, Langevin E, Petigara T, Boeri M. Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S318-9. doi: 10.1016/j.jval.2023.09.1679

Cadarette S, Rementeria MA, Espinosa EG, Stewart F, Brisibe T, Devani D, Kistler K, Oladapo T, Rangi ND, Wissinger E. Quality of life (QOL) instruments used in clinicaltrials.gov-indexed trials of gene-modified cell therapy (GMCT) in patients with multiple myeloma (MM). Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S495. doi: 10.1016/j.jval.2023.09.2676

Erbe AW, Kendzia D, Busink E, Carroll S, Aas E. Value of an integrated home dialysis model in the United Kingdom: a cost-effectiveness analysis. Value Health. 2023 Jul;26(7):984-94. doi: 10.1016/j.jval.2023.02.009

Gnanasakthy A, Norcross L, Fitzgerald K. Editorial - Assessment of patient-reported outcomes in industry-sponsored phase 1 oncology studies: considerations for translating theory into practice. Value Health. 2023 Jun 21;26(10):1440-3. doi: 10.1016/j.jval.2023.06.006

Aris E, Brabant Y, La E, Candrilli S, Molnar D. Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States: a retrospective claims database analysis. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S124. doi: 10.1016/j.jval.2023.03.657

Jimenez M, Zanotti G, Parikh RC, Esterberg E, Suarez LA. A retrospective medical record review of first-line sunitinib administration schedules and outcomes among patients with metastatic renal cell carcinoma in Latin America. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S45. doi: 10.1016/j.jval.2023.03.2298

Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S78. doi: 10.1016/j.jval.2023.03.405

Dong O, Purser M, Herring WL, Mladsi DM, Gallagher M, Chawla A, Leiding JW, Andemariam B. Relationships among sickle cell disease complications and their implications for cost-effectiveness modeling for therapies with curative intent. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S115-6. doi: 10.1016/j.jval.2023.03.611

Zhang KH, Winfree K, Taipale KL, Muehlenbein CE, Panjic EH, Graham C. Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S187. doi: 10.1016/j.jval.2023.03.1013

Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S172. doi: 10.1016/j.jval.2023.03.927

Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME. Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S349. doi: 10.1016/j.jval.2023.03.2378

Poulos C, Mansfield C, Bussberg CJ, Hicks JC, Downey C. Advancing equity, diversity, inclusion, and belonging in patient centered drug development with patient preference research. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S359. doi: 10.1016/j.jval.2023.03.2791

Poulos C, Pierce A, Chintakayala PK. A review of the influence of stakeholder preference research on the EtR framework. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S347. doi: 10.1016/j.jval.2023.03.2370

Houghton K, Hitchens A, Ciepielewska M. Healthcare resource use and costs among patients with erythropoietic protoporphyria and x-linked protoporphyria in the United States. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S155. doi: 10.1016/j.jval.2023.03.2501

Grant S, Gold A, Pavisic I, Doma R, Rudell K. Using qualitative methods to develop grounded relevant content for preference surveys in a Specific Rare Bleeding Disorder (SRBD). Poster presented at the ISPOR 2023; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 Supplement):S327. doi: 10.1016/j.jval.2023.03.1864

Janssen E, Smith I, Liu X, Mansfield C, Pierce A, Huang Q, Kalsekar I. Patient preferences for lung cancer interception therapy. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S343. doi: 10.1016/j.jval.2023.03.1943

Nangia A, Simou E, Abeysinghe S, Colosia A, Bektas M, Workman J, Gao S, Bello N. Incidence rate of infections and association between lupus nephritis and serious infections in patients with systemic lupus erythematosus: systematic literature review and meta-analyses. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S180. doi: 10.1016/j.jval.2023.03.972

Mordin M, Castro C, Gnanasakthy A. Trends in the inclusion of patient reported outcomes in oncology clinical trials: analysis of clinicaltrials.gov (2013-2022). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S325. doi: 10.1016/j.jval.2023.03.1852

Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderås M, Ling C, Marcano Belisario J. HTA processes for medical technologies across the world – are all hurdles the same? Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S272-3. doi: 10.1016/j.jval.2023.03.1503

Graham J, Kassouf W, Tomaras D, Kurt M, Patel M, Teitsson S. Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: a Canada public payer perspective. Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S66-7. doi: 10.1016/j.jval.2023.03.347

McMichael A, Poulos C, Vass C, Boeri M. A literature review assessing the most common attributes used in stated-preference studies assessing influenza vaccination: do we know what health care professionals value? Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S329-30. doi: 10.1016/j.jval.2023.03.1876

Verelst F, La E, Graham J, Molnar D. Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S120. doi: 10.1016/j.jval.2023.03.632

Yousif Z, Schultz BG, Candela N, Harold S, Bell J, Turpin R, Hartley L. Systematic literature review to evaluate randomized clinical trials of advanced therapies for moderate to severe crohn's disease. Poster presented at the ISPOR 2023 Conference; May 6, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S15. doi: 10.1016/j.jval.2023.03.085

Fernandez M, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Burden of surgery in desmoid tumors. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S22. doi: 10.1016/j.jval.2023.03.117

Gohil S, Johnson ML, Goyal R. Impact of a cancer diagnosis on non-cancer chronic disease medication adherence - a systematic literature review. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S197. doi: 10.1016/j.jval.2023.03.1064

Frederiksen KS, Crawford R, Hahn-Pedersen JH, Morrison R, Jeppesen R, Doward L, Weidner W. Insights from social media posts on the lived experience of alzheimer's disease. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S352. doi: 10.1016/j.jval.2023.03.2395

Korgaonkar S, Prajapati P, Barnard M, Goswami S. Evaluation of the association between self-perceptions of aging and care deferrals among US adults aged 50 years or older during the COVID-19 pandemic. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S338. doi: 10.1016/j.jval.2023.03.1920

Doma R, Gold A, Gregg M, Brouwer ES, Rudell K. A secondary analysis of the cross-cultural validation of multi-dimensional postpartum health PROMs, and suggestions for improving their validity and administration. Poster presented at the ISPOR 2023; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 Supplement):S189. doi: 10.1016/j.jval.2023.03.1021

Wissinger E, Koufopoulou M, Fusco N, Stewart F, Oladapo T, Depalma S, Devani D, Rangi ND. Surrogate endpoints in oncology: a review of recent health technology appraisals in the United Kingdom. Poster presented at the ISPOR 2023; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 Suppl):S265-6. doi: 10.1016/j.jval.2023.03.1470

Koufopoulou M, Wissinger E, Oladapo T, Stewart F, Depalma S, Devani D, Rangi ND, Fusco N. The use of real-world data in decision making for oncology: a review of recent health technology appraisals in the United Kingdom. Poster presented at the ISPOR 2023; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 Suppl):S262. doi: 10.1016/j.jval.2023.03.1453

Johnson ML, Yande S, Aparasu RR, Wanat M, Toale K. Prevalence and factors associated with the use of direct oral anticoagulants and low molecular weight heparins (LMWH) in cancer patients. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S377-8. doi: 10.1016/j.jval.2023.03.2121

Gnanasakthy A, Levy C, Norcross L, Doward L, Winnette R. A review of labeling based on patient reported outcome endpoints for new oncology drugs approved by the European Medicines Agency (2017-2021). Value Health. 2023 Jun;26(6):893-901. doi: 10.1016/j.jval.2023.01.017

Kosa K, Mutebi A, Wang A, Blaedel J, Sacchi M, Martin S. Improvements in symptoms, impact of treatment, and satisfaction with treatment among patients with relapsed or refractory b-cell non-hodgkin lymphoma treated with subcutaneous epcoritamab. Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S315. doi: 10.1016/j.jval.2023.03.1800

McLeod LD, Rockwood NJ. Editorial - Comparability among modes of data collection for patient-reported outcome measures: opening the gates for faithful migration. Value Health. 2023 May;26(5):620-2. doi: 10.1016/j.jval.2023.03.010

Li X, Hodgson D, Flaig J, Kieffer A, Herring WL, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P, REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. Value Health. 2023 Apr;26(4):508-18. doi: 10.1016/j.jval.2022.11.014

Mladsi D, Barnett CL, Mader G, Russell-Smith TA, Tuson H, Unuigbe A, Bell T. The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price. Value Health. 2023 Mar;26(3):384-91. doi: 10.1016/j.jval.2023.01.004.

Cotter SP, Schwartz L, Strong TV, Bender RH, Fehnel S. The Prader-Willi syndrome anxiousness and distress behaviors questionnaire: development and psychometric validation. Value Health. 2023 Feb 1;26(2):243-50. doi: 10.1016/j.jval.2022.08.004

Weissert S, Mikkelsen EM, Jacobsen BH, Hatch EE, Wesselink AK, Wise LA, Rothman KJ, Sorensen HT, Laursen ASD. Organic food consumption and fecundability in a preconception cohort study of Danish couples trying to conceive. Paediatr Perinat Epidemiol. 2023 Jan;37(1):57-68. doi: 10.1111/ppe.12924

Ni L, Diamantogiannis F, Teitsson S, Knight C. Cost-effectiveness analysis of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in Greece. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S120. doi: 10.1016/j.jval.2022.09.580

Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Assessing the cost-effectiveness of the Novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S89. doi: 10.1016/j.jval.2022.09.434

Paret K, Ronquest N, Droege M. Economic modeling considerations for rare neurodegenerative diseases of infancy and early childhood. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S171. doi: 10.1016/j.jval.2022.09.830